Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 15/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23691548 | 0.96 | NLRP3 (0.44) | NLRP3ALDH1A1ATMSMN1; SMN2MAPT | |
| SCHEMBL19506009 | 0.82 | NLRP3 (0.44) | NLRP3ALDH1A1ATMSMN1; SMN2MAPT | |
| SCHEMBL25833609 | 0.79 | NLRP3 (0.49) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL19505705 | 0.76 | NLRP3 (0.46) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL25820382 | 0.74 | NLRP3 (0.42) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL26590829 | 0.74 | NLRP3 (0.45) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL24130016 | 0.73 | NLRP3 (0.51) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL22011174 | 0.72 | NLRP3 (0.44) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL20692248 | 0.72 | NLRP3 (0.44) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL22251965 | 0.72 | MAPT (0.53) | NLRP3ALDH1A1ATMSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880666-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| EP-3445757-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RES INC (US) | 2020-11-25 | — | — | EP | disclosed |